openPR Logo
Press release

Chemotherapy-Induced Nausea And Vomiting Therapeutics Market– Innovation Survey 2027

03-04-2019 03:13 PM CET | Health & Medicine

Press release from: future market insights.

Chemotherapy-Induced Nausea And Vomiting Therapeutics

Cancer is a leading cause of death worldwide, accounting nearly 1.4 million new cases in 2012. The most common cause of cancer is lung cancer accounting about 1.59 million deaths, globally. Other prominent cancers are liver cancer, breast cancer, stomach cancer, esophageal and stomach cancer. In 2012, nearly 8.2 million deaths occurred from aforementioned indication, globally. Cancer can be treated by surgery, chemotherapy, radiation therapy, hormone therapy, targeted therapy, precision medicine and stem cell transplantation. The most common treatment for cancer is chemotherapy; it uses drugs to kill cancer cells that cause pain and other problems. Chemotherapy may be used in combination with other cancer treatments. Chemotherapy given before surgery and radiation therapy to make the tumor cell smaller is known as neo-adjuvant chemotherapy and chemotherapy given after treatment with surgery or radiation therapy is known as adjuvant chemotherapy.

Chemotherapy, not only kills the cancer cells but also attacks healthy cells that leads to side effects such as fatigue, hair loss, nausea, and vomiting. Chemotherapy-Induced Nausea and Vomiting (CINV) is one of the most serious side effects that is taken into account. Chemotherapy-induced nausea and vomiting are classified as acute, that occurs within 24 hours of the treatment; anticipatory, that is triggered due to some exposed stimuli; other are refractory; delayed and breakthrough. Incidence, timing, and intensity of chemotherapy-induced nausea and vomiting vary on chemotherapeutic agents and patient factors. CINV occurs in about 80% of patients and has a severe impact on patient’s life.

A Sample Of This Report Is Available Upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2957

Antiemetics are less effective in controlling nausea and vomiting because the intensity is high than actual vomiting. Proper antiemetics can prevent CINV in about 60%-70% of patients. Nowadays due to research and development in the field of cancer therapeutics, many treatment options are available to manage and treat CINV by addressing antiemetic property to an individual patient. Conventionally Chemotherapy-Induced Nausea and Vomiting was managed with dopamine receptor antagonists only. Currently, multiple options are available that is used in the prevention and management of CINV.

Chemotherapy-induced Nausea and Vomiting Therapeutics Market: Drivers and Restrains

According to Word Health Organization, it is estimated that by 2030, about 23.6 million new cases of cancer will prevail worldwide. Agents are available for the treatment of chemotherapy-induced nausea and vomiting NK1 receptor antagonists, corticosteroids, -HT3 receptor antagonists and others. Governmental guidelines from American Society of Clinical Oncology and National Comprehensive Cancer Network (NCCN /ASCO) are providing help to healthcare professionals to manage antiemetic regimens for patients. Intense research and development in cancer therapeutics, the rise in the incidence of cancer cases, increased preference toward chemotherapy for the treatment of cancer and the use of chemotherapy in combination with other cancer treatment are anticipated to fuel the growth of chemotherapy-induced nausea and vomiting. The decline in the use of chemotherapy drugs in future can decline the growth of chemotherapy-induces nausea and vomiting therapeutics market.

Chemotherapy-induced Nausea and Vomiting Therapeutics Market: Segmentation

The global chemotherapy-induced nausea and vomiting therapeutics market has been classified by therapy type, route of administration, distribution channel, and geography. Based on Therapy Type, the Chemotherapy-induced Nausea and Vomiting Therapeutics Market is divided into following: Dopamine ntagonists, Serotonin Receptor Antagonists, Corticosteroids, Benzodiazepines, Neurokinin NK1 receptor antagonist ; Based on the Route of Administration, the global Chemotherapy-induced Nausea and Vomiting Therapeutics Market is divided into following: Oral, Intravenous; Based on the Distribution Channel, the global Chemotherapy-induced Nausea, and Vomiting Therapeutics Market is divided into following: Hospital Pharmacy, Drug Stores, Retail Pharmacy, E-commerce.

Chemotherapy-induced Nausea and Vomiting Therapeutics Market: Overview

Based on the therapy type, the global chemotherapy-induced nausea and vomiting therapeutics market is segmented into dopamine antagonists, serotonin receptor antagonists, corticosteroids, benzodiazepines, and neurokinin NK1 receptor antagonist. Serotonin receptor antagonists are said to account the major share in the chemotherapy-induced nausea and vomiting therapeutics market as it is most commonly used and is effective. It blocks the binding of serotonin to its receptor, thus stopping the signal to the brain. By route of administration the chemotherapy-induced nausea and vomiting therapeutics market is segmented into oral and intravenous administration. Based on the distribution channel the CINV market is segmented into hospital pharmacy, drug store, retail pharmacy, and e-commerce. The rise in cancer patient population, funding by the governmental bodies, focus on acquisition and merger by various key manufacturers is attributed towards the growth of chemotherapy-induced nausea and vomiting therapeutics.

Chemotherapy-induced Nausea and Vomiting Therapeutics Market: Regional Overview

Region-wise, the global Chemotherapy-induced Nausea and Vomiting Therapeutics Market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. More than 70% of world's cancer death occurs in Africa, Asia, and South America. Around 33% of cancer cases worldwide are due to smoke and tobacco. Along with expansion in the emerging markets, and a greater focus on early diagnosis, screening, monitoring and clinical development of CINV drugs have been the major strategies adopted by major players in the global chemotherapy-induced nausea and vomiting therapeutics market.

Read Comprehensive Overview with Methodology of Report @ https://www.futuremarketinsights.com/toc/rep-gb-2957

Chemotherapy-induced Nausea and Vomiting Therapeutics Market: Key Players

Some of the key players in global Chemotherapy-induced Nausea and Vomiting Therapeutics Market are GlaxoSmithKline plc, Merck & Co., Inc, Teva Pharmaceuticals, Heron Therapeutics, Inc., F. Hoffmann-La Roche AG, Tesaro, Inc., Acacia Pharma, Baxter international Inc., Lee's Pharmaceutical Holdings, Mundipharma International limited, Kyowa Hakko Kirin Co., Ltd.and others.

Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centres in the U.S. and India.
FMI’s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customised and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.

Future Market Insights
U.S. Office
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: abhishek.b@futuremarketinsights.com
FMI Blog:  https://www.fmiblog.com/
Web: https://www.futuremarketinsights.com
Blog: http://www.marketresearchblog.org/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Chemotherapy-Induced Nausea And Vomiting Therapeutics Market– Innovation Survey 2027 here

News-ID: 1630459 • Views: 313

More Releases from future market insights.

Facial Implants Market 2018 - 2028 | Key Players Include Implatech Associates In …
Facial implants are a type of medical device used to correct the facial structure or to provide more defined facial features including cheeks or chin & jawline. Facial Implants products are used for cosmetic reasons & are also used in medical crises such as accidents and injuries. Facial implants are also designed for augmentative or reconstructive surgeries. Facial implants give long lasting and permanent results that are a key factor
Pericarditis Treatment Market 2018 - 2028 | Pfizer Inc., Bayer AG, PerkinElmer I …
Global Pericarditis Treatment: Market Insights  Pericarditis is a cardiovascular disease which represents the swelling of the pericardium wall of the heart. The main cause of pericardium disease is the inflammation of pericardium wall which is generally caused by viral infection. Other causes of pericarditis disease are renal failure, bacterial infections and intake of some drugs such as procainamide. Some of the common symptoms of pericarditis disease are shortness of breath, fatigue, rapid
Aldosteronism Treatment Market Drivers and Restraints | 2018 - 2028 Key Players …
Aldosteronism is a type of hormonal disorder that occurs due to an imbalance in aldosterone and further leads to high blood pressure. In Aldosteronism, aldosterone is produced in excess by the adrenal gland that exceeds the normal body requirement. This causes the sodium levels to increase and lowers the potassium levels in the body. High levels of sodium in the blood lead to a high volume of blood and ultimately
Contouring Implants Market 2018 - 2028 | Key Players are ALPHA-HEALTH (ASIA) PTE …
Body Contouring refers to the medical-surgical procedure that alternates the shape of parts of the body via the removal of fat or skin. Body contouring implants procedures includes reshaping and resizing certain areas so the persons overall appearance is more balanced and in proportion. Body contouring implants are foreign materials that is made and molded prior to the person’s surgery and then inserted into the appropriate site. The body contouring

All 5 Releases


More Releases for Chemotherapy

Chemotherapy Induced Neutropenia Market Report by MarketResearchReports.biz
"The Latest Research Report Chemotherapy Induced Neutropenia-Pipeline Review, H1 2018 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Neutropenia - Pipeline Review, H1 2018, provides an overview of the Chemotherapy Induced Neutropenia (Toxicology) pipeline landscape. Chemotherapy-induced neutropenia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness,
Chemotherapy Induced Anemia - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Chemotherapy Induced Anemia - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Anemia - Pipeline Review, H2 2017, provides an overview of the Chemotherapy Induced Anemia (Toxicology) pipeline landscape. Chemotherapy-induced anemia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness,
Nano Chemotherapy Market Nano Chemotherapy Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Nano Chemotherapeutics Mediations andndash; Solicitation to Nanomedicine 1.1 Overview 1.2 Nano Chemotherapeutics with Pharmaceutical Potential Significance of Nano Chemotherapeutics to overcome the Chemotherapy Limitations 2.1 Limitations of Conventional Chemotherapy 2.2 Nanotechnology in Cancer Targeting 2.2.1 Active Targeting 2.2.2 Passive Targeting 2.2.3 pH Dependent Drug Delivery Through Nanoparticles Role
Global Chemotherapy Pumps Sales Market Report 2017
This report studies sales (consumption) of Chemotherapy Pumps in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering Bayer Healthcare Becton & Dickson GE Medical BMS Celsus Laboratories Johnson and Johnson CME Medical Codman and Shurtleff Takeda Novartis Covidien D. Medical Industries Danone Nutricia Debiotech Alcor Scientific Alkermes Allied Medical Generex Biotechnology Corporation Trivitron Valeritas Vectura Vishal Surgical WalkMed Inc Zevex Hospira To Get Sample Copy of Report visit @ http://www.qyresearchreports.com/sample/sample.php?rep_id=984092&type=E Market Segment by Regions,
Chemotherapy Pump Market Research Report 2017
Global Chemotherapy Pump Industry 2021 Market Research Report analyzed the current state in the definitions, classifications, applications and industry chain structure. The report also focuses on the development trends as well as history, competitive landscape analysis, and key regions etc in the international markets. Global Chemotherapy Pump Industry 2021 Market Research Report is a professionally prepared report comprising of in-depth information as well as knowledge which is helpful to the new
09-22-2016 | Health & Medicine
bmr
2020 Chemotherapy Market Globally analysis
“Global Chemotherapy Market Research Report 2016” Order This Report by calling BigMarketResearch.com at +1-971-202-1575 Notes: Production, means the output of Chemotherapy Revenue, means the sales value of Chemotherapy This report studies Chemotherapy in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with Production, price, revenue and market share for each manufacturer, covering Pfizer Inc. (USA) Abbott Laboratories (USA) Genentech Inc. (USA) GlaxoSmithKline Plc (UK) Immunomedics, Inc. (USA) Indevus